posted 10-06-2005 06:48 PM         

WHITEHOUSE STATION, N.J., Oct. 6, 2005 - GARDASILTM (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine), an investigational vaccine from Merck & Co., Inc., prevented 100 percent of high-grade cervical pre-cancers and non-invasive cervical cancers (CIN 2/3 and AIS) associated with human papillomavirus (HPV) types 16 and 18 in a new phase III study. The analysis compared GARDASIL to placebo in women who were not infected with HPV 16 and 18 at enrollment and who remained free of infection through the completion of the vaccination regimen. Women were followed for an average of two years after enrollment. Tomorrow these data will be presented for the first time at the Infectious Diseases Society of America (IDSA) annual meeting.

This trial is part of the ongoing phase III program for GARDASIL, which involves over 25,000 people in 33 countries worldwide. Merck remains on track to submit a Biologics License Application for GARDASIL to the Food and Drug Administration in the fourth quarter of 2005.

More than 12,000 women from 13 countries participated in this trial

posted 10-06-2005 07:51 PM         

Merck up 39 cents after hour trading $27.22.
52 week high $35.36

Now all we need to hear is some good news from Intel, Cisco, Microsoft, Broadcom, Ariba, Sun, JDS and all the Retailers.

We also need all the Fed representatives to not talk until the market ends. The markets took a real nose dive this week.